Acta Neuropathol Commun. 2015 Apr 3;3:18. doi: 10.1186/s40478-015-0188-0.
The prion protein (PrP) binds to various molecular partners, but little is known about their potential impact on the pathogenesis of prion diseases
Here, we show that PrP can interact in vitro with acetylcholinesterase (AChE), a key protein of the cholinergic system in neural and non-neural tissues. This heterologous association induced aggregation of monomeric PrP and modified the structural properties of PrP amyloid fibrils. Following its recruitment into PrP fibrils, AChE loses its enzymatic activity and enhances PrP-mediated cytotoxicity. Using several truncated PrP variants and specific tight-binding AChE inhibitors (AChEis), we then demonstrate that the PrP-AChE interaction requires two mutually exclusive sub-sites in PrP N-terminal domain and an aromatic-rich region at the entrance of AChE active center gorge. We show that AChEis that target this site impair PrP-AChE complex formation and also limit the accumulation of pathological prion protein (PrPSc) in prion-infected cell cultures. Furthermore, reduction of AChE levels in prion-infected heterozygous AChE knock-out mice leads to slightly but significantly prolonged incubation time. Finally, we found that AChE levels were altered in prion-infected cells and tissues, suggesting that AChE might be directly associated with abnormal PrP.
Our results indicate that AChE deserves consideration as a new actor in expanding pathologically relevant PrP morphotypes and as a therapeutic target.
朊病毒蛋白(PrP)与各种分子伴侣结合,但关于它们对朊病毒病发病机制的潜在影响知之甚少。
在这里,我们表明 PrP 可以在体外与乙酰胆碱酯酶(AChE)相互作用,AChE 是神经和非神经组织中胆碱能系统的关键蛋白。这种异源结合诱导单体 PrP 的聚集,并改变 PrP 淀粉样纤维的结构特性。AChE 被募集到 PrP 纤维后,会失去其酶活性,并增强 PrP 介导的细胞毒性。使用几种截短的 PrP 变体和特异性紧密结合的 AChE 抑制剂(AChEis),我们进一步证明 PrP-AChE 相互作用需要 PrP N 端结构域中的两个相互排斥的亚位点和 AChE 活性中心峡谷入口处富含芳香族的区域。我们表明,针对该位点的 AChEis 会破坏 PrP-AChE 复合物的形成,并限制朊病毒感染细胞培养物中病理性朊病毒蛋白(PrPSc)的积累。此外,在朊病毒感染的杂合 AChE 敲除小鼠中降低 AChE 水平会导致潜伏期略有但显著延长。最后,我们发现朊病毒感染的细胞和组织中 AChE 水平发生改变,表明 AChE 可能与异常 PrP 直接相关。
我们的结果表明,AChE 值得考虑作为扩展与病理相关的 PrP 形态的新因素,以及作为治疗靶点。